Costs variations for percutaneous nephrolithotomy in the U.S. from 2003–2015: A contemporary analysis of an all-payer discharge database

Auteurs-es

  • Jeffrey J. Leow 1Division of Urology and Center for Surgery and Public Health, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 2Department of Urology, Tan Tock Seng Hospital, Singapore
  • Anne-Sophie Valiquette 3Department of Urology, Université de Montréal, Montréal, Quebec, Canada
  • Benjamin I. Chung 4Department of Urology, Stanford University, Stanford, CA
  • Steven L. Chang 1Division of Urology and Center for Surgery and Public Health, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 5Lank Center for Genitourinary Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA
  • Quoc-Dien Trinh 1Division of Urology and Center for Surgery and Public Health, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 5Lank Center for Genitourinary Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA
  • Rus Korets 6Veterans Affairs Boston Healthcare System, Harvard Medical School, Boston, MA
  • Naeem Bhojani University of Montreal

DOI :

https://doi.org/10.5489/cuaj.5280

Résumé

Introduction: We sought to evaluate population-based cost variations and predictors of outlier costs for percutaneous nephrolithotomy (PCNL) in the U.S.

Methods: Using the Premier Healthcare Database, we identified all patients diagnosed with kidney/ureter calculus who underwent PCNL from 2003–2015. We evaluated 90-day direct hospital costs, defining high- and low-cost surgery as those >90th and <10th percentile, respectively. We constructed a multilevel, hierarchical regression model and calculated the pseudo-R2 of each variable, which translates to the percentage variability contributed by that variable on 90-day direct hospital costs.

Results: A total of 114 581 patients underwent PCNL during the 12-year study period. Mean cost in the low-cost group was $5787 (95% confidence interval [CI] 5716–5856) vs. $38 590 (95% CI 37 357–39 923) in the high-cost group. Cost variations were substantially impacted by patient (63.7%) and surgical (18.5%) characteristics and less so by hospital characteristics (3.9%). Significant predictors of high costs included more comorbidities (≥2 vs. 0: odds ratio [OR] 1.81; p=0.01) and hospital region (Northeast vs. Midwest: OR 2.04; p=0.03). Predictors of low cost were hospital bed size of 300–499 beds (OR 1.35; p<0.01) and urban hospitals (OR 2.77; p=0.01). Factors less likely to be associated with lowcost PCNL were more comorbidities (Charlson Comorbidity Index [CCI] ≥2: OR 0.69; p<0.0001), larger hospitals (OR 0.61; p=0.01), and teaching hospitals (OR 0.33; p<0.0001).

Conclusions: Our contemporary analysis demonstrates that patient and surgical characteristics had a significant effect on costs associated with PCNL. Poor comorbidity status contributed to high costs, highlighting the importance of patient selection.

Téléchargements

Les données relatives au téléchargement ne sont pas encore disponibles.

Publié-e

2018-06-19

Comment citer

Leow, J. J., Valiquette, A.-S., Chung, B. I., Chang, S. L., Trinh, Q.-D., Korets, R., & Bhojani, N. (2018). Costs variations for percutaneous nephrolithotomy in the U.S. from 2003–2015: A contemporary analysis of an all-payer discharge database. Canadian Urological Association Journal, 12(12). https://doi.org/10.5489/cuaj.5280

Numéro

Rubrique

Original Research